Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer Beitrags-Navigation Zurück Vorheriger Beitrag: Gulf Coast Express Pipeline LLC Announces Binding Open Season for Limited Remaining CapacityWeiter Nächster Beitrag: The Buckle, Inc. Announces the Election of Kari G. Smith to the Company’s Board of Directors and Other Leadership Appointments